share_log

BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4

Benzinga ·  Nov 29, 2023 07:31

BTIG analyst Julian Harrison assumes Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment